The expansion of India's QR code-based drug traceability framework to vaccines, antimicrobials, and anti-cancer drugs represents a paradigm shift in pharmaceutical governance. Critically examine the policy rationale, implementation challenges, and public health implications.

Q. The expansion of India's QR code-based drug traceability framework to vaccines, antimicrobials, and anti-cancer drugs represents a paradigm shift in pharmaceutical governance. Critically examine the policy rationale, implementation challenges, and public health implications. (15 marks, 250 words)

India, the "pharmacy of the world", has long battled spurious and sub-standard medicines. The June 2026 notification extending Schedule H2 QR/bar-code traceability under the Drugs Rules, 1945 to vaccines, antimicrobials, anti-cancer and narcotic drugs signals a genuine, if incremental, shift toward a digitally verifiable supply chain [1].

Policy rationale - Anti-counterfeiting: unit-level QR enables end-to-end tracing (manufacturer→patient) and patient-side authentication via a software application [1]. - Phased continuity: builds on APIs (2022) and the top-300 brands mandate (G.S.R. 823(E), effective Aug 2023) — administrative realism, not a leap [2]. - AMR containment: tracing antimicrobials curbs irrational and grey-market dispensing, a WHO priority.

Implementation challenges - Digital divide: rural chemists and patients often lack smartphones or reader access. - Compliance cost burdens MSME manufacturers lacking serialisation infrastructure. - Authentication is meaningless without an integrated central repository. - Field enforcement rests with state drug controllers (Concurrent List) — capacity gaps persist. - Staggered timelines (antimicrobials only from 2028) dilute urgency [1].

Public health implications - Shields UIP vaccines and high-cost oncology drugs from life-threatening fakes. - NDPS traceability [3] curbs diversion for abuse, but must not deny palliative-care access. - Enables rapid batch recall and pharmacovigilance.

The framework is a welcome move from prescription control toward digital assurance. Its promise hinges on pairing mandates with reader infrastructure, a central database and MSME support — advancing SDG-3 and the right to safe medicines.

(~250 words)

Sources: 1. Union Health Ministry expands QR code-based drug traceability framework — PIB / MoHFW (June 2026) — Schedule H2 expanded to vaccines, antimicrobials, anti-cancer, NDPS drugs; phased dates (vaccines/anti-cancer/narcotics from 1 July 2026, antimicrobials from 1 July 2028) 2. Bar/QR Code implementation on top 300 brands — G.S.R. 823(E), MoHFW (17 Nov 2022, effective 1 Aug 2023) — phased rollout, primary/secondary label placement, software-readable authentication 3. The Narcotic Drugs and Psychotropic Substances Act, 1985 — India Code, GoI — statutory basis for narcotic/psychotropic drugs brought under Schedule H2